Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany.
During the last few years, deep brain stimulation (DBS) of the subthalamic nucleus (STN) has emerged as a promising therapy, alleviating major motor symptoms of Parkinson's disease (PD). However, in times of growing budgetary limitations, medical decisions are no longer merely based on clinical efficacy, but also on cost-effectiveness. Here we assess treatment costs (i. e. costs for conservative pharmacological treatment and all in-patient admissions) of 46 PD patients for one year before and two years after STN-DBS. The present data show that total treatment costs were increased by 32% for the first year and decreased by 54% for the second year of STN-DBS in comparison with preoperative values while the Unified Parkinson's Disease Rating Scale (UPDRS III) was significantly improved. The increase for the first year after surgery was mainly due to the implantation of the STN electrodes and the stimulation device. Taken together, STNDBS pays off from the second year of stimulation while motor symptoms are significantly improved. The present study provides first data of an important number of patients on clinical effectiveness and expenses in relation to STNDBS.
Meissner
Wassilios
W
Department of Neurology, Charité Campus Virchow-Klinikum, Humboldt University, Augustenburger Platz 1, 13353 Berlin, Germany. wassilios.meissner@charite.de
Schreiter
Doreen
D
Volkmann
Jens
J
Trottenberg
Thomas
T
Schneider
Gerd-Helge
GH
Sturm
Volker
V
Deuschl
Guenther
G
Kupsch
Andreas
A
D000704:Analysis of Variance; D003365:Costs and Cost Analysis; D046690:Deep Brain Stimulation / Q000191:economics* / Q000379:methods; D004358:Drug Therapy / Q000191:economics / Q000379:methods; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000191:economics* / Q000628:therapy; D012189:Retrospective Studies; D013223:Statistics as Topic; D016896:Treatment Outcome
J Neurol. 2002 Jun;249(6):759-66
12111311
Lancet. 1997 Dec 6;350(9092):1676
9400515
N Engl J Med. 1998 Oct 15;339(16):1105-11
9770557
Neurology. 2000;55(12 Suppl 6):S45-51
11188975
Trends Pharmacol Sci. 2004 May;25(5):249-53
15120490
Health Policy. 1996 May;36(2):155-66
10158766
Neurosurgery. 1999 Dec;45(6):1375-82; discussion 1382-4
10598706
Neurology. 1998 Sep;51(3):850-5
9748038
Neurology. 1999 Jul 13;53(1):85-90
10408541
J Gen Intern Med. 1997 Sep;12(9):551-8
9294789
Klin Wochenschr. 1960 Dec 15;38:1236-9
13726012
Neurology. 2001 Feb 27;56(4):548-51
11222806
N Engl J Med. 2003 Nov 13;349(20):1925-34
14614167
Mov Disord. 2002;17 Suppl 3:S94-101
11948762
CMAJ. 1992 Feb 15;146(4):473-81
1306034
Neurology. 2001 Aug 28;57(4):663-71
11524476
Pharmacoeconomics. 2001;19(10):1013-38
11735671
Rev Neurol (Paris). 2000;156 Suppl 2 Pt 2:270-3
10916057